Getinge Boston Consulting Group Matrix
See the Bigger Picture
Curious where Getinge’s products fall—Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a practical roadmap for capital allocation. Purchase the complete report to get a polished Word analysis plus an Excel summary you can edit and present—skip the guesswork and act with confidence. Get instant access and start steering strategy, not just guessing at it.
Stars
ICU ventilators (Servo)
Getinge's Servo ICU ventilators occupy a Star position in a rapidly evolving critical care market, backed by strong clinical credibility and an installed base of tens of thousands of devices worldwide. Demand remains driven by ICU modernization and resilience spending, sustaining high growth (market CAGR ~6–7%). Leadership requires heavy training, system integrations and ongoing clinical evidence. With continued investment they can mature into cash cows as growth cools.
ECMO & cardiopulmonary support
ECMO adoption keeps climbing as more centers build capability and guidelines expand; ELSO reports over 100,000 ECMO runs to date. Getinge’s systems are front-row, benefiting from strong brand trust in high-acuity care and a sizable installed base. Growth consumes cash for clinician training, disposables and service coverage—investments that seed recurring consumables and service revenue. Hold share now to convert spending into rich, steady platforms later.
Hybrid OR integration
Hospitals consolidate procedures into image-guided, high-throughput hybrid ORs, driving demand for integrated tables, booms and software; the hybrid OR market is expanding with a mid-single-digit CAGR in 2024. Getinge’s tables, booms and integration layer fit imaging partners, giving the company leadership and negotiation clout. The segment is capex-heavy, requires KOL engagement and long sales cycles, but repeat wins compound revenue and margin upside.
Life science isolators & sterilization for biopharma
Life-science isolators and sterilization are critical for biologics and advanced therapies that require airtight aseptic workflows; the global biologics market was ~USD 350B in 2024 and the sterilization equipment market ~USD 6B (2024), while cell and gene therapy activity exceeded 2,000 trials by 2024, driving demand. Getinge’s isolators and sterilizers benefit from strong reference sites and adoption in this fast-growing segment.
- High demand: biologics ~USD 350B (2024)
- Market tailwind: sterilization equipment ~USD 6B (2024)
- Resource intensity: applications, support, validation soak engineering time
- Strategic upside: dominance → long-term profit engine
Infection prevention leadership
Heightened focus on HAIs keeps high-end decontamination in the spotlight; the global infection prevention market reached about USD 34.6 billion in 2024 with ~6.4% CAGR, and Getinge’s portfolio leads complex reprocessing and containment use cases, driving robust growth while education and change-management impose significant implementation costs.
- Market 2024: USD 34.6B, CAGR 6.4%
- Getinge: leadership in complex reprocessing
- Trade-off: strong growth vs. real training/implementation costs
- Strategy: invest now to lock share as standards tighten
Ventilators, ECMO & sterilization: durable platform, 6–7% ventilator CAGR
Getinge Stars: Servo ICU ventilators hold tens of thousands installed, market CAGR ~6–7% (2024) and need ongoing training to convert to cash cows. ECMO adoption >100,000 runs (ELSO) fuels consumables/service revenue but demands upfront investment. Sterilization/isolators tie to biologics ~USD 350B and sterilization equipment ~USD 6B (2024), creating durable platform upside.
| Segment | 2024 metric | CAGR/notes |
|---|---|---|
| Servo ventilators | tens of thousands installed | 6–7% CAGR |
| ECMO | >100,000 runs | growing consumables |
| Sterilization | equipment USD 6B; biologics USD 350B | 6.4% infection prevention CAGR |
What is included in the product
Detailed Word Document
Concise BCG review of Getinge products with strategic moves for Stars, Cash Cows, Question Marks and Dogs, plus investment recommendations.
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant to pinpoint pain areas and prioritize investments.
Cash Cows
Sterile reprocessing equipment
Core sterilizers and washer-disinfectors sit in a mature, replacement-driven market where Getinge, with reported 2024 sales of SEK 36.8 billion, leverages a deep installed base and leading share in sterile reprocessing. Margins are solid, benefiting from low promotional need and steady service pull-through that drives recurring revenue. Prioritize milking the base while investing in manufacturing and service efficiencies to widen cash flow and ROIC.
Surgical tables & OR lights
Surgical tables and OR lights sit on established OR infrastructure with predictable 7–10 year refresh cycles and a high market share in many regions, backed by proven reliability and steady tender flow. Low-to-moderate market growth and recurring service revenues—around 20–30% of product lifecycle revenue—make them cash cows for Getinge. Strategy: maintain leadership, optimize manufacturing and supply-chain costs, and defend pricing power in tenders and aftermarket contracts.
Cardiopulmonary perfusion systems
Open-heart volumes remain steady year-over-year, with CABG procedures broadly flat in 2023–24, supporting predictable demand for perfusion. Getinge’s established perfusion platforms have a loyal installed base, driving high attach rates and repeat business. Cash generation is dominated by disposables, service and paid upgrades rather than heavy promotional spend. Maintain reliability and tight margins to protect recurring profitability.
Service & maintenance contracts
Service & maintenance contracts drive recurring revenue from Getinge’s large installed base; in 2024 services represented roughly one-third of group sales and delivered high margins. Renewal rates exceed 80% when uptime remains top-tier, keeping cash generation reliable while growth is modest. Expanding remote diagnostics can raise utilization and squeeze more efficiency from existing assets.
- Installed base: backbone for recurring revenue
- Renewal rate: >80% with high uptime
- Margin: high, cash-generative
- Opportunity: scale remote diagnostics
Consumables & accessories
Procedural and reprocessing consumables drive recurring pull-through at Getinge, supporting FY2024 operating cash flow with stable volumes and low branding spend; market growth in 2024 was muted but Getinge maintained sturdy share in core segments. Margins are healthy and predictable, enabling pricing discipline while emphasizing supply-chain protection to avoid service disruptions.
- High recurring revenue
- Muted 2024 market growth, stable share
- Good margins, predictable volumes
- Low marketing spend; protect supply chain
- Maintain pricing discipline
Installed-base cash cows: services ~33%, renewals >80% - milk aftermarket margins
Getinge’s core sterilizers, OR equipment, perfusion platforms and consumables are cash cows: FY2024 sales SEK 36.8 billion, services ~33% of group sales, renewal rates >80% and high aftermarket margins driving stable free cash flow. Focus on milking installed base, cutting manufacturing/service costs and scaling remote diagnostics to lift ROIC. Protect supply chain to preserve recurring revenue.
| Metric | 2024 |
|---|---|
| Total sales | SEK 36.8bn |
| Services share | ~33% |
| Renewal rate | >80% |
What You See Is What You Get
Getinge BCG Matrix
The file you're previewing is the final Getinge BCG Matrix you'll receive after purchase—no watermarks, no demo text, just a fully formatted, strategy-ready report. This preview matches the downloadable file exactly, crafted for clarity and quick presentation to stakeholders. After purchase you'll get the same editable document delivered instantly to your inbox. Use it for planning, pitches, or internal review with zero surprises.
See the Bigger Picture
Curious where Getinge’s products fall—Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a practical roadmap for capital allocation. Purchase the complete report to get a polished Word analysis plus an Excel summary you can edit and present—skip the guesswork and act with confidence. Get instant access and start steering strategy, not just guessing at it.
Stars
ICU ventilators (Servo)
Getinge's Servo ICU ventilators occupy a Star position in a rapidly evolving critical care market, backed by strong clinical credibility and an installed base of tens of thousands of devices worldwide. Demand remains driven by ICU modernization and resilience spending, sustaining high growth (market CAGR ~6–7%). Leadership requires heavy training, system integrations and ongoing clinical evidence. With continued investment they can mature into cash cows as growth cools.
ECMO & cardiopulmonary support
ECMO adoption keeps climbing as more centers build capability and guidelines expand; ELSO reports over 100,000 ECMO runs to date. Getinge’s systems are front-row, benefiting from strong brand trust in high-acuity care and a sizable installed base. Growth consumes cash for clinician training, disposables and service coverage—investments that seed recurring consumables and service revenue. Hold share now to convert spending into rich, steady platforms later.
Hybrid OR integration
Hospitals consolidate procedures into image-guided, high-throughput hybrid ORs, driving demand for integrated tables, booms and software; the hybrid OR market is expanding with a mid-single-digit CAGR in 2024. Getinge’s tables, booms and integration layer fit imaging partners, giving the company leadership and negotiation clout. The segment is capex-heavy, requires KOL engagement and long sales cycles, but repeat wins compound revenue and margin upside.
Life science isolators & sterilization for biopharma
Life-science isolators and sterilization are critical for biologics and advanced therapies that require airtight aseptic workflows; the global biologics market was ~USD 350B in 2024 and the sterilization equipment market ~USD 6B (2024), while cell and gene therapy activity exceeded 2,000 trials by 2024, driving demand. Getinge’s isolators and sterilizers benefit from strong reference sites and adoption in this fast-growing segment.
- High demand: biologics ~USD 350B (2024)
- Market tailwind: sterilization equipment ~USD 6B (2024)
- Resource intensity: applications, support, validation soak engineering time
- Strategic upside: dominance → long-term profit engine
Infection prevention leadership
Heightened focus on HAIs keeps high-end decontamination in the spotlight; the global infection prevention market reached about USD 34.6 billion in 2024 with ~6.4% CAGR, and Getinge’s portfolio leads complex reprocessing and containment use cases, driving robust growth while education and change-management impose significant implementation costs.
- Market 2024: USD 34.6B, CAGR 6.4%
- Getinge: leadership in complex reprocessing
- Trade-off: strong growth vs. real training/implementation costs
- Strategy: invest now to lock share as standards tighten
Ventilators, ECMO & sterilization: durable platform, 6–7% ventilator CAGR
Getinge Stars: Servo ICU ventilators hold tens of thousands installed, market CAGR ~6–7% (2024) and need ongoing training to convert to cash cows. ECMO adoption >100,000 runs (ELSO) fuels consumables/service revenue but demands upfront investment. Sterilization/isolators tie to biologics ~USD 350B and sterilization equipment ~USD 6B (2024), creating durable platform upside.
| Segment | 2024 metric | CAGR/notes |
|---|---|---|
| Servo ventilators | tens of thousands installed | 6–7% CAGR |
| ECMO | >100,000 runs | growing consumables |
| Sterilization | equipment USD 6B; biologics USD 350B | 6.4% infection prevention CAGR |
What is included in the product
Detailed Word Document
Concise BCG review of Getinge products with strategic moves for Stars, Cash Cows, Question Marks and Dogs, plus investment recommendations.
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant to pinpoint pain areas and prioritize investments.
Cash Cows
Sterile reprocessing equipment
Core sterilizers and washer-disinfectors sit in a mature, replacement-driven market where Getinge, with reported 2024 sales of SEK 36.8 billion, leverages a deep installed base and leading share in sterile reprocessing. Margins are solid, benefiting from low promotional need and steady service pull-through that drives recurring revenue. Prioritize milking the base while investing in manufacturing and service efficiencies to widen cash flow and ROIC.
Surgical tables & OR lights
Surgical tables and OR lights sit on established OR infrastructure with predictable 7–10 year refresh cycles and a high market share in many regions, backed by proven reliability and steady tender flow. Low-to-moderate market growth and recurring service revenues—around 20–30% of product lifecycle revenue—make them cash cows for Getinge. Strategy: maintain leadership, optimize manufacturing and supply-chain costs, and defend pricing power in tenders and aftermarket contracts.
Cardiopulmonary perfusion systems
Open-heart volumes remain steady year-over-year, with CABG procedures broadly flat in 2023–24, supporting predictable demand for perfusion. Getinge’s established perfusion platforms have a loyal installed base, driving high attach rates and repeat business. Cash generation is dominated by disposables, service and paid upgrades rather than heavy promotional spend. Maintain reliability and tight margins to protect recurring profitability.
Service & maintenance contracts
Service & maintenance contracts drive recurring revenue from Getinge’s large installed base; in 2024 services represented roughly one-third of group sales and delivered high margins. Renewal rates exceed 80% when uptime remains top-tier, keeping cash generation reliable while growth is modest. Expanding remote diagnostics can raise utilization and squeeze more efficiency from existing assets.
- Installed base: backbone for recurring revenue
- Renewal rate: >80% with high uptime
- Margin: high, cash-generative
- Opportunity: scale remote diagnostics
Consumables & accessories
Procedural and reprocessing consumables drive recurring pull-through at Getinge, supporting FY2024 operating cash flow with stable volumes and low branding spend; market growth in 2024 was muted but Getinge maintained sturdy share in core segments. Margins are healthy and predictable, enabling pricing discipline while emphasizing supply-chain protection to avoid service disruptions.
- High recurring revenue
- Muted 2024 market growth, stable share
- Good margins, predictable volumes
- Low marketing spend; protect supply chain
- Maintain pricing discipline
Installed-base cash cows: services ~33%, renewals >80% - milk aftermarket margins
Getinge’s core sterilizers, OR equipment, perfusion platforms and consumables are cash cows: FY2024 sales SEK 36.8 billion, services ~33% of group sales, renewal rates >80% and high aftermarket margins driving stable free cash flow. Focus on milking installed base, cutting manufacturing/service costs and scaling remote diagnostics to lift ROIC. Protect supply chain to preserve recurring revenue.
| Metric | 2024 |
|---|---|
| Total sales | SEK 36.8bn |
| Services share | ~33% |
| Renewal rate | >80% |
What You See Is What You Get
Getinge BCG Matrix
The file you're previewing is the final Getinge BCG Matrix you'll receive after purchase—no watermarks, no demo text, just a fully formatted, strategy-ready report. This preview matches the downloadable file exactly, crafted for clarity and quick presentation to stakeholders. After purchase you'll get the same editable document delivered instantly to your inbox. Use it for planning, pitches, or internal review with zero surprises.
Description
See the Bigger Picture
Curious where Getinge’s products fall—Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a practical roadmap for capital allocation. Purchase the complete report to get a polished Word analysis plus an Excel summary you can edit and present—skip the guesswork and act with confidence. Get instant access and start steering strategy, not just guessing at it.
Stars
ICU ventilators (Servo)
Getinge's Servo ICU ventilators occupy a Star position in a rapidly evolving critical care market, backed by strong clinical credibility and an installed base of tens of thousands of devices worldwide. Demand remains driven by ICU modernization and resilience spending, sustaining high growth (market CAGR ~6–7%). Leadership requires heavy training, system integrations and ongoing clinical evidence. With continued investment they can mature into cash cows as growth cools.
ECMO & cardiopulmonary support
ECMO adoption keeps climbing as more centers build capability and guidelines expand; ELSO reports over 100,000 ECMO runs to date. Getinge’s systems are front-row, benefiting from strong brand trust in high-acuity care and a sizable installed base. Growth consumes cash for clinician training, disposables and service coverage—investments that seed recurring consumables and service revenue. Hold share now to convert spending into rich, steady platforms later.
Hybrid OR integration
Hospitals consolidate procedures into image-guided, high-throughput hybrid ORs, driving demand for integrated tables, booms and software; the hybrid OR market is expanding with a mid-single-digit CAGR in 2024. Getinge’s tables, booms and integration layer fit imaging partners, giving the company leadership and negotiation clout. The segment is capex-heavy, requires KOL engagement and long sales cycles, but repeat wins compound revenue and margin upside.
Life science isolators & sterilization for biopharma
Life-science isolators and sterilization are critical for biologics and advanced therapies that require airtight aseptic workflows; the global biologics market was ~USD 350B in 2024 and the sterilization equipment market ~USD 6B (2024), while cell and gene therapy activity exceeded 2,000 trials by 2024, driving demand. Getinge’s isolators and sterilizers benefit from strong reference sites and adoption in this fast-growing segment.
- High demand: biologics ~USD 350B (2024)
- Market tailwind: sterilization equipment ~USD 6B (2024)
- Resource intensity: applications, support, validation soak engineering time
- Strategic upside: dominance → long-term profit engine
Infection prevention leadership
Heightened focus on HAIs keeps high-end decontamination in the spotlight; the global infection prevention market reached about USD 34.6 billion in 2024 with ~6.4% CAGR, and Getinge’s portfolio leads complex reprocessing and containment use cases, driving robust growth while education and change-management impose significant implementation costs.
- Market 2024: USD 34.6B, CAGR 6.4%
- Getinge: leadership in complex reprocessing
- Trade-off: strong growth vs. real training/implementation costs
- Strategy: invest now to lock share as standards tighten
Ventilators, ECMO & sterilization: durable platform, 6–7% ventilator CAGR
Getinge Stars: Servo ICU ventilators hold tens of thousands installed, market CAGR ~6–7% (2024) and need ongoing training to convert to cash cows. ECMO adoption >100,000 runs (ELSO) fuels consumables/service revenue but demands upfront investment. Sterilization/isolators tie to biologics ~USD 350B and sterilization equipment ~USD 6B (2024), creating durable platform upside.
| Segment | 2024 metric | CAGR/notes |
|---|---|---|
| Servo ventilators | tens of thousands installed | 6–7% CAGR |
| ECMO | >100,000 runs | growing consumables |
| Sterilization | equipment USD 6B; biologics USD 350B | 6.4% infection prevention CAGR |
What is included in the product
Detailed Word Document
Concise BCG review of Getinge products with strategic moves for Stars, Cash Cows, Question Marks and Dogs, plus investment recommendations.
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant to pinpoint pain areas and prioritize investments.
Cash Cows
Sterile reprocessing equipment
Core sterilizers and washer-disinfectors sit in a mature, replacement-driven market where Getinge, with reported 2024 sales of SEK 36.8 billion, leverages a deep installed base and leading share in sterile reprocessing. Margins are solid, benefiting from low promotional need and steady service pull-through that drives recurring revenue. Prioritize milking the base while investing in manufacturing and service efficiencies to widen cash flow and ROIC.
Surgical tables & OR lights
Surgical tables and OR lights sit on established OR infrastructure with predictable 7–10 year refresh cycles and a high market share in many regions, backed by proven reliability and steady tender flow. Low-to-moderate market growth and recurring service revenues—around 20–30% of product lifecycle revenue—make them cash cows for Getinge. Strategy: maintain leadership, optimize manufacturing and supply-chain costs, and defend pricing power in tenders and aftermarket contracts.
Cardiopulmonary perfusion systems
Open-heart volumes remain steady year-over-year, with CABG procedures broadly flat in 2023–24, supporting predictable demand for perfusion. Getinge’s established perfusion platforms have a loyal installed base, driving high attach rates and repeat business. Cash generation is dominated by disposables, service and paid upgrades rather than heavy promotional spend. Maintain reliability and tight margins to protect recurring profitability.
Service & maintenance contracts
Service & maintenance contracts drive recurring revenue from Getinge’s large installed base; in 2024 services represented roughly one-third of group sales and delivered high margins. Renewal rates exceed 80% when uptime remains top-tier, keeping cash generation reliable while growth is modest. Expanding remote diagnostics can raise utilization and squeeze more efficiency from existing assets.
- Installed base: backbone for recurring revenue
- Renewal rate: >80% with high uptime
- Margin: high, cash-generative
- Opportunity: scale remote diagnostics
Consumables & accessories
Procedural and reprocessing consumables drive recurring pull-through at Getinge, supporting FY2024 operating cash flow with stable volumes and low branding spend; market growth in 2024 was muted but Getinge maintained sturdy share in core segments. Margins are healthy and predictable, enabling pricing discipline while emphasizing supply-chain protection to avoid service disruptions.
- High recurring revenue
- Muted 2024 market growth, stable share
- Good margins, predictable volumes
- Low marketing spend; protect supply chain
- Maintain pricing discipline
Installed-base cash cows: services ~33%, renewals >80% - milk aftermarket margins
Getinge’s core sterilizers, OR equipment, perfusion platforms and consumables are cash cows: FY2024 sales SEK 36.8 billion, services ~33% of group sales, renewal rates >80% and high aftermarket margins driving stable free cash flow. Focus on milking installed base, cutting manufacturing/service costs and scaling remote diagnostics to lift ROIC. Protect supply chain to preserve recurring revenue.
| Metric | 2024 |
|---|---|
| Total sales | SEK 36.8bn |
| Services share | ~33% |
| Renewal rate | >80% |
What You See Is What You Get
Getinge BCG Matrix
The file you're previewing is the final Getinge BCG Matrix you'll receive after purchase—no watermarks, no demo text, just a fully formatted, strategy-ready report. This preview matches the downloadable file exactly, crafted for clarity and quick presentation to stakeholders. After purchase you'll get the same editable document delivered instantly to your inbox. Use it for planning, pitches, or internal review with zero surprises.
